- Companies
- Rgenta Therapeutics
Rgenta Therapeutics Funding, Investors & Competitors
Rgenta Therapeutics has raised $159M across 7 funding rounds, most recently a $42M Series B in November 2026.
Last Rgenta Therapeutics funding round
$42M
Series B · Nov 2026
Cumulative funding Rgenta Therapeutics raised
$159M
across 7 funding rounds
Key investors in Rgenta Therapeutics
Kaitai Capital
Matrix Partners China
Lilly Asia Ventures
Vivo Capital
Legend Star
Boehringer Ingelheim Venture Fund
CICC
Highlight Capital
About Rgenta Therapeutics
Rgenta Therapeutics is a Cambridge, Massachusetts-headquartered biotech firm developing oral small-molecule drugs targeting RNA splicing for oncology indications. Founded in 2018, its platform analyzes genomics datasets to identify spliceosome modulators that glue regulatory proteins to aberrant RNAs in cancers like solid tumors. Rgenta advances three preclinical programs against undruggable targets, raising $50 million in Series A funding from ARCH Venture Partners and others.
Founded
2018
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Rgenta Therapeutics Funding History
Rgenta Therapeutics has raised a total of $159M across 7 funding rounds.
Rgenta Therapeutics' first fundraising round was a $10M Series A in January 2020. The most recent completed round was a $42M Series B in November 2026.
Rgenta Therapeutics funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Nov 2026 | Series B | - | $42M | Rgenta Therapeutics, Inc. sold USD 41.85 million of Series B preferred stock to nine investors, according to a Form D dated November 3, 2026 and filed with the US Securities and Exchange Commission. The offering covers Series B-1 and Series B-2 preferred stock and non-voting special preferred stock with a total size of up to USD 130.1 million, and the first sale took place in October 2026. The filing does not name the investors. Rgenta is a Massachusetts biotechnology company developing small molecules that target RNA, with its lead programme RGT-61159 in a Phase 1a/b trial in adenoid cystic carcinoma and colorectal cancer. The company has a research collaboration with GSK on RNA-targeting treatments. It raised a USD 52 million Series A in November 2022. |
| May 2023 | Series A | Highlight Capital (lead); The Leukemia & Lymphoma Society’s Therapy Acceleration Program | $8M | - |
| Nov 2022 | Series A | AstraZeneca (lead); CICC (lead); Matrix Partners China; Kaitai Capital; Boehringer Ingelheim Venture Fund; Delos Capital; Korean Investment Partners; Vivo Capital; Lilly Asia Ventures; Legend Star | $52M | AZ-CICC Healthcare Investment Fund led a USD 52 million Series A financing in Rgenta Therapeutics, announced on 29 November 2022, with participation from all existing investors and new investors Korean Investment Partners and Delos Capital. Existing backers include Boehringer Ingelheim Venture Fund, Kaitai Capital, Legend Star, Lilly Asia Ventures, Matrix Partners China and Vivo Capital. The company said it would use the proceeds to speed up development of its lead programs, enhance target discovery, extend its platform capabilities and advance a pipeline of RNA-targeting programs against a range of disease indications. Co-founder and chief executive Simon Xi said the company was grateful to its existing investors and pleased to welcome the new ones. Rgenta develops oral small-molecule medicines that target RNA, with an initial focus on oncology and neurological disorders. Its platform mines human genomics data to identify targetable RNA processing events and designs small-molecule glues that modulate interactions among the spliceosome, regulatory proteins and RNAs. The company was founded in 2018 and is based in the United States. Valuation was not disclosed. |
| Feb 2022 | Series A | - | $9M | Rgenta Therapeutics is a Cambridge, Massachusetts-based biotech company developing a pipeline of oral, small-molecule RNA-targeting medicines for historically undruggable disease targets, with initial focus on oncology and neurology. The company utilizes a proprietary platform that analyzes massive amounts of human genomics data to identify regulatory sites in RNAs amenable to selective modulation by small molecules, then rapidly screens for drug-like candidates. In November 2022, Rgenta closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund (a joint venture between AstraZeneca and China International Capital Corporation) with participation from existing investors and new investors including Korean Investment Partners and Delos Capital. The company planned to use the proceeds to accelerate development of its lead programs, enhance target discovery capabilities, extend platform functionality, and advance its RNA-targeting pipeline across multiple disease indications toward clinical development. Rgenta's earlier seed financing was led by a syndicate including Boehringer Ingelheim Venture Fund, Matrix Partners China, Lilly Asia Venture, and Vivo Capital. |
| May 2021 | Seed | Kaitai Capital; Vivo Capital; Lilly Asia Ventures | $18M | Rgenta Therapeutics, based in Woburn, Massachusetts, develops oral small-molecule RNA-targeting medicines focused on oncology and neurological disorders. The company uses a proprietary platform that analyzes genomics data to identify targetable RNA processing events and designs small-molecule glues to modulate spliceosome, regulatory protein, and RNA interactions, targeting historically undruggable diseases. On May 25, 2021, Rgenta announced the closing of an $18 million seed extension round, welcoming new investors Lilly Asia Ventures (LAV) and Vivo Capital, along with additional contribution from Kaitai Capital. This followed an initial seed round in 2020 co-led by BIVF and Matrix Capital Management with other early investors, bringing total funding raised to $38 million at that point. The proceeds were intended to accelerate the pipeline toward clinical development and expand programs against RNA targets in oncology and neurological diseases. Later rounds included a Series A - II for $8M on May 23, 2023, and additional seed and Series A financings in 2022. |
| Apr 2020 | Seed | Boehringer Ingelheim Venture Fund (lead); Matrix Partners China (lead); Kaitai Capital; Legend Star | $20M | Rgenta Therapeutics launched in April 2020 with a $20 million seed investment co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. The company focuses on developing small-molecule drugs that target RNA regulation and splicing to treat cancer and neurological diseases, with its scientific foundation based on work by cofounder Zhiping Weng from the University of Massachusetts Medical School. The proprietary platform mines massive genomics data to identify targetable RNA processing events and design small-molecule modulators to regulate interactions among the spliceosome, regulatory proteins, and RNAs. As an early-stage biotech startup at the time of this initial seed round, Rgenta had not yet generated commercial revenue. The company subsequently raised additional funding, including an $18 million seed extension in May 2021 led by Lilly Asia Venture and Vivo Capital, and a $52 million Series A in November 2022 led by AZ-CICC Healthcare Investment Fund, demonstrating sustained investor confidence in the RNA-targeting therapeutic approach. |
| Jan 2020 | Series A | - | $10M | - |
Who has invested in Rgenta Therapeutics?
12 investors have backed Rgenta Therapeutics across its funding rounds, including Kaitai Capital, Matrix Partners China, Lilly Asia Ventures, Vivo Capital, Legend Star and Boehringer Ingelheim Venture Fund.
Lead investors include Highlight Capital, AstraZeneca, CICC, Boehringer Ingelheim Venture Fund and Matrix Partners China.
Rgenta Therapeutics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Apr 2020 | ||
| 2 | Lead | Apr 2020 | ||
| 2 | Lead | Apr 2020 | ||
| 2 | Participant | May 2021 | ||
| 2 | Participant | May 2021 | ||
| 2 | Participant | Apr 2020 | ||
| 1 | Lead | Nov 2022 | ||
| 1 | Participant | Nov 2022 | ||
| 1 | Lead | May 2023 | ||
| 1 | Participant | Nov 2022 | ||
This data is available for Pro users. Sign up to see all 12 Rgenta Therapeutics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialRgenta Therapeutics Competitors
Rgenta Therapeutics competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Anthropic and OpenAI.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3.8B | - | ||
| Private | $48M | - | $3.8B | - | ||
| Private | $47B | - | $965B | 20.5x | ||
| Private | $25B | - | $852B | 34.1x | ||
| Publicly listed | $41B | $13B | $273B | 6.1x | ||
| Publicly listed | $4.7B | ($1.3B) | $97B | 16.4x |
Rgenta Therapeutics Public Comps
Rgenta Therapeutics is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, SAP, Amgen and IBM.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 19.2x | 14.3x | 45.1x | 30.2x | |||
| $94B | $40B | 7.4x | 6.9x | 17.3x | 18.8x | |||
| $61B | $17B | 9.6x | 8.8x | 33.7x | 18.6x | |||
| $78B | $26B | 5.3x | 5.3x | 15.7x | 13.3x | |||
| $65B | $28B | 6.2x | 6.1x | 14.5x | 22.9x | |||
| $57B | $22B | 6.1x | 6.1x | 15.9x | 14.8x | |||
| $59B | $19B | 5.4x | 5.1x | 16.5x | 14.2x | |||
| $41B | $13B | 6.6x | 6.1x | 20.9x | 19.0x | |||
This data is available for Pro users. Sign up to see all Rgenta Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Rgenta Therapeutics
| When was Rgenta Therapeutics founded? | Rgenta Therapeutics was founded in 2018. |
| Where is Rgenta Therapeutics headquartered? | Rgenta Therapeutics is headquartered in United States. |
| Is Rgenta Therapeutics publicly listed? | No, Rgenta Therapeutics is a private, VC-backed company. |
| How much funding has Rgenta Therapeutics raised? | Rgenta Therapeutics has raised $159M across 7 funding rounds. |
| What was Rgenta Therapeutics' last funding round? | Rgenta Therapeutics' last funding round was a $42M Series B in November 2026. |
| Who are Rgenta Therapeutics' investors? | Rgenta Therapeutics' investors include Kaitai Capital, Matrix Partners China, Boehringer Ingelheim Venture Fund, Vivo Capital, Lilly Asia Ventures, Legend Star, AstraZeneca, Delos Capital, Highlight Capital, Korean Investment Partners and 2 others. |
| Which companies are comparable to Rgenta Therapeutics? | Companies comparable to Rgenta Therapeutics include Astromech, Chai Discovery, Anthropic, OpenAI, SAP and Snowflake. |
See companies similar to Rgenta Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




